In this issue:
Blunted and transient response to SARS-CoV-2 vaccination in inflammatory disease
Treat-to-target TNF inhibitor dose tapering non-inferior for low disease activity in PsA
Meta-analysis reports high efficacy of JAK inhibitors for PsA
Dactylitis is associated with severe axial joint damage and high disease activity
TNF inhibitors confer a delayed benefit in radiographic sacroiliitis progression
The occurrence of multiple biologic treatment switches in axSpA in Nordic countries
Mood disorders hamper PsA improvement
Driving difficulties are common in axSpA and negatively impact work
Ustekinumab is effective across a range of outcomes for PsA
Tofacitinib predominantly relieves pain indirectly via inflammation reduction
Please login below to download this issue (PDF)